α-synuclein suppression by targeted small interfering rna in the primate substantia nigra

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  McCormack, Alison L ^a,b   Mak, Sally K ^c   Henderson, Jaimie M ^d   Bumcrot, David ^e   Farrer, Matthew J ^f   Di Monte, Donato A ^a,b  

^a GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^b SRI INTERNATIONAL   (United States)

^c PARKINSON S INSTITUTE   (United States)

^d STANFORD UNIVERSITY   (United States)

^e ALNYLAM PHARMACEUTICALS   (United States)

^f MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; ENDONUCLEASE; EXONUCLEASE; LUCIFERASE; MESSENGER RNA; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG SAFETY; DRUG TARGETING; FEASIBILITY STUDY; FEMALE; INFLAMMATION; LEFT HEMISPHERE; MALE; MONKEY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIMATE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RIGHT HEMISPHERE; RNA INTERFERENCE; SUBSTANTIA NIGRA; ANIMAL; CEBIDAE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; METHODOLOGY;

ANIMALIA; PRIMATES;

ALPHA-SYNUCLEIN; ANIMALS; BASE SEQUENCE; DOPAMINE; FEMALE; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; MALE; RNA, SMALL INTERFERING; SAIMIRI; SUBSTANTIA NIGRA;

EID: 77957877526     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012122     Document Type: Article

References (35)

1. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. (1997) Mutation in the α-Synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
2. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, et al. (1998) Ala30Pro mutation in the gene encoding α-Synuclein in Parkinson's disease. Nat Genet 18: 106-108.
3. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, et al. (2003) α-Synuclein locus triplication causes Parkinson's disease. Science 302: 841.
4. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, et al. (2004) The new mutation, E46K, of α-Synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55: 164-173.
5. Farrer M, Kachergus J, Forno L, Lincoln S, Wang DS, et al. (2004) Comparison of kindreds with parkinsonism and α-Synuclein genomic multiplications. Ann Neurol 55: 174-179.
6. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goerdert M (1998) α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 95: 6469-6473.
7. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, et al. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197-211.
8. Tu PH, Galvin JE, Baba M, Giasson B, Tomita T, et al. (1998) Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α-Synuclein. Ann Neurol 44: 415-422.
9. Trojanowski JQ, Revesz T, Neuropathology Working Group on MSA (2007) Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol 33: 615-620.
10. Conway KA, Rochet JC, Bieganski RM, Lansbury PT (2001) Kinetic stabilization of the α-Synuclein protofibril by a dopamine-α-Synuclein adduct. Science 294: 1346-1349.
11. Uversky VN (2007) Neuropathology, biochemistry, and biophysics of asynuclein aggregation. J Neurochem 103: 17-37.
12. Eslamboli A, Romero-Ramos M, Burger C, Björklund T, Muzyczka N, et al. (2007) Long-term consequences of human α-Synuclein overexpression in the primate ventral midbrain. Brain 130: 799-815.
13. Cookson MR (2009) α-Synuclein and neuronal cell death. Mol Neurodegener 4: 9.
14. Lee VM, Trojanowski JQ (2006) Mechanisms of Parkinson's disease linked to pathological α-Synuclein: new targets for drug discovery. Neuron 52: 33-38.
15. Gonzales-Alegre P, Paulson HL (2007) Technology Insight: therapeutic RNA interference-how far from the neurology clinic? Nat Clin Prac Neurol 3: 394-404.
16. Fountaine TM, Venda LL, Warrick N, Christian HC, Brundin P, et al. (2008) The effect of α-Synuclein knockdown on MPP+ toxicity in models of human neurons. Eur J Neurosci 28: 2459-2473.
17. Sapru MK, Yates JW, Hogan S, Jiang L, Halter J, et al. (2006) Silencing of human α-Synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp Neurol 198: 382-390.
18. Lewis J, Melrose H, Bumcrot D, Hope A, Zehr C, et al. (2008) In vivo silencing of α-Synuclein using naked siRNA. Mol Neurodegener 3: 19.
19. Gorbatyuk OS, Li S, Nash K, Gorbatyuk M, Lewin AS, et al. (2010) In vivo RNAi-mediated α-Synuclein silencing induces nigrostriatal degeneration. Mol Ther. In press.
20. Chu Y, Kordower JH (2007) Age-associated increases of α-Synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease? Neurobiol Dis 25: 134-149.
21. Mak SK, McCormack AL, Langston JW, Kordower JH, Di Monte DA (2009) Decreased α-Synuclein in the aging mouse substantia nigra. Exp Neurol 220: 359-365.
22. McCormack AL, Mak SK, Shenasa M, Langston WJ, Forno LS, et al. (2008) Pathologic modifications of α-Synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-treated squirrel monkeys. J Neuropathol Exp Neurol 67: 793-802.
23. Emmers R, Akert K (1963) A stereotaxic atlas of the brain of the squirrel monkey. Madison: University of Wisconsin Press.
24. Purisai MG, McCormack AL, Langston JW, Johnston LC, Di Monte DA (2005) α-Synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol Dis 20: 898-906.
25. Drury S, Anderson H, Dowsett M (2009) Selection of REFERENCE genes for normalization of qRT-PCR data derived from FFPE breast tumors. Diagn Mol Pathol 18: 103-107.
26. McCormack AL, Di Monte DA, Delfani K, Irwin I, DeLanney LE, et al. (2004) Aging of the nigrostriatal system in the squirrel monkey. J Comp Neurol 471: 387-395.
27. Clayton DF, George JM (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. J Neurosci Res 58: 120-129.
28. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, et al. (2000) Mice lacking α-Synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25: 239-252.
29. Lou H, Montoya SE, Alerte TN, Wang J, Wu J, et al. (2010) Serine 129 phosphorylation reduces α-Synuclein's ability to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo. J Biol Chem 285: 17648-17661.
30. Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC (2003) α-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 278: 25009-25013.
31. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D (2004) Impaired degradation of mutant α-Synuclein by chaperone-mediated autophagy. Science 305: 1292-1295.
32. Mak SK, McCormack AL, Manning-Bog AB, Cuervo AM, Di Monte DA (2010) Lysosomal degradation of α-Synuclein in vivo. J Biol Chem 285: 13621-13629.
33. Tansey MG, McCoy MK, Frank-Cannon TC (2007) Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 208: 1-25.
34. Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8: 382-397.
35. Al-Wandi A, Ninkina N, Millership S, Williamson SJ, Jones PA, et al. (2010) Absence of α-Synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice. Neurobiol Aging 31: 796-804.